Delving into the Latest Updates on Compound danshen dripping pills with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

compound danshen dripping pills

+ [3]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [5]

Active Indication

Diabetic RetinopathyAngina PectorisAblepharon Macrostomia Syndrome+ [1]

Inactive Indication

Angina, Stable

Originator Organization

Tasly Pharmaceutical Group Co., Ltd.

Active Organization

Tasly Pharmaceutical Group Co., Ltd.Tasly Pharmaceuticals, Inc.

Inactive Organization

Arbor Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1994),

Angina Pectoris

Regulation-

Login to view timeline

This study is designed to evaluate the efficacy and safety of compound Danshen dropping pills (CDDP) in improving ventricular remodeling and cardiac function after acute anterior wall ST-Elevation myocardial infarction(STEMI). 268 patients with acute anterior wall STEMI after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to CDDP group(n=134) and control group(n=134) with follow-up of 24 weeks. Both groups are treated with standard therapy of STEMI, with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets three times a day after pPCI and the control group treated with placebo at the same time. The primary endpoint is 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI).The secondary endpoint is the change in N terminal pro-B-type natriuretic peptide（NT-proBNP ）level, arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).

Start Date25 Aug 2021

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

NCT04993729 / CompletedPhase 3

A Multicenter, Double-blind, Randomized and Placebo-controlled Pivotal Phase 3 Study to Evaluate the Safety and Efficacy of T89 in the Prevention and Treatment of Acute Mountain Sickness (AMS) After Rapid Ascent

The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.

Start Date21 Jul 2021

Sponsor / Collaborator

Tasly Pharmaceuticals, Inc.

100 Clinical Results associated with Compound danshen dripping pills

Login to view more data

100 Translational Medicine associated with Compound danshen dripping pills

Login to view more data

100 Patents (Medical) associated with Compound danshen dripping pills

Login to view more data

68

Literatures (Medical) associated with Compound danshen dripping pills

03 Oct 2024·Journal of Pharmacy and Pharmacology

Network pharmacology prediction, molecular docking, and molecular dynamics simulation-based strategy to explore the potential mechanism of Huashanshen dripping pill against asthma

Article

Author: Wu, Yujie ; Jin, Xin ; Liu, Rui ; Wang, Xiaoyu ; Ji, Yansu ; Zhou, Miaomiao ; Feng, Jihong ; Xu, Yanhong

AbstractObjectivesAsthma is a heterogeneous disease characterized by chronic airway inflammation. Huashanshen dripping pills (HSS) are commonly utilized for relieving asthma, relieving cough, and expelling phlegm. At present, the molecular mechanism against airway inflammation remains unclear.MethodsIn this study, network pharmacology, molecular docking technology, and molecular dynamic simulation were used to predict the therapeutic pathways of HSS for asthma. The ovalbumin-induced mouse model was used to further validate the prediction by RT-qPCR, western blot, immunofluorescence, and related methods.Key findingsThe findings indicate that HSS improves lung function and relieves lung inflammation by reducing inflammatory cell infiltration around the bronchus and reducing eosinophilic counts in bronchoalveolar lavage fluid (BALF). In addition, it lowers the levels of inflammatory cytokines and the expression levels of interleukin-4, interleukin-5, and interleukin-13 mRNA. HSS also inhibits the phosphorylation and nuclear translocation of NF-κB p65 protein.ConclusionsAll results suggested that HSS can decrease airway inflammation in asthmatic mice by inhibiting NF-κB signaling pathway. This finding will shed light on how it can be used to treat asthma.

01 Jul 2024·Phytomedicine

Research of the dynamic regulatory mechanism of Compound Danshen Dripping Pills on myocardial infarction based on metabolic trajectory analysis

Article

Author: He, Jiang-Hua ; Zhang, Cai-Juan ; Zhong, Lin-Ying ; Sun, Jing ; Zhu, Bo ; Yu, Zhi-Ying ; Dong, Ling ; Qu, Xiao-Yang ; Xu, Wen-Juan ; Yang, Jie ; Zhu, Yu-Xin

BACKGROUNDMyocardial infarction (MI) is a serious cardiovascular disease, which presents different pathophysiological changes with the prolongation of the disease. Compound danshen dripping pills (CDDP) has obvious advantages in MI treatment and widely used in the clinic. However, the current studies were mostly focused on the endpoint of CDDP intervention, lacking the dynamic attention to the disease process. It is of great value to establish a dynamic research strategy focused on the changes in pharmacodynamic substances for guiding clinical medication more precisely.PURPOSEIt is aimed to explore the dynamic regulating pattern of CDDP on MI based on metabolic trajectory analysis, and then clarify the variation characteristic biomarkers and pharmacodynamic substances in the intervention process.METHODSThe MI model was successfully prepared by coronary artery left anterior descending branch ligation, and then CDDP intervention was given for 28 days. Endogenous metabolites and the components of CDDP in serum were measured by LC/MS technique simultaneously to identify dynamic the metabolic trajectory and screen the characteristic pharmacodynamic substances at different points. Finally, network pharmacology and molecular docking techniques were used to simulate the core pharmacodynamic substances and core target binding, then validated at the genetic and protein level by Q-PCR and western blotting technology.RESULTSCDDP performed typical dynamic regulation features on metabolite distribution, biological processes, and pharmacodynamic substances. During 1-7 days, it mainly regulated lipid metabolism and inflammation, the Phosphatidylcholine (PC(18:1(9Z/18:1(9Z)) and Sphingomyelin (SM(d18:1/23:1(9Z)), SM(d18:1/24:1(15Z)), SM(d18:0/16:1(9Z))) were the main characteristic biomarkers. Lipid metabolism was the mainly regulation pathway during 14-21 days, and the characteristic biomarkers were the Lysophosphatidylethanolamine (LysoPE(0:0/20:0), PE-NMe2(22:1(13Z)/15:0)) and Sphingomyelin (SM(d18:1/23:1(9Z))). At 28 days, in addition to inflammatory response and lipid metabolism, fatty acid metabolism also played the most important role. Correspondingly, Lysophosphatidylcholine (LysoPC(20:0/0:0)), Lysophosphatidylserine (LPS(18:0/0:0)) and Fatty acids (Linoelaidic acid) were the characteristic biomarkers. Based on the results of metabolite distribution and biological process, the characteristic pharmacodynamic substances during the intervention were further identified. The results showed that various kinds of Saponins and Tanshinones as the important active ingredients performed a long-range regulating effect on MI. And the other components, such as Tanshinol and Salvianolic acid B affected Phosphatidylcholine and Sphingomyelin through Relaxin Signaling pathway during the early intervention. Protocatechualdehyde and Rosmarinic acid affected Lysophosphatidylethanolamine and Sphingomyelin through EGFR Tyrosine kinase inhibitor resistance during the late intervention. Tanshinone IIB and Isocryptotanshinone via PPAR signaling pathway affected Lysophosphatidylcholine, Lysophosphatidylserine, and Fatty acids.CONCLUSIONThe dynamic regulating pattern was taken as the entry point and constructs the dynamic network based on metabolic trajectory analysis, establishes the dynamic correlation between the drug-derived components and the endogenous metabolites, and elucidates the characteristic biomarkers affecting the changes of the pharmacodynamic indexes, systematically and deeply elucidate the pharmacodynamic substance and mechanism of CDDP on MI. It also enriched the understanding of CDDP and provided a methodological reference for the dynamic analysis of complex systems of TCM.

01 Jun 2024·Phytomedicine

Compound Danshen Dripping Pill effectively alleviates cGAS-STING-triggered diseases by disrupting STING-TBK1 interaction

Article

Author: Li, Hui ; Bai, Zhaofang ; Wang, Zhongxia ; Zhang, Ping ; Shi, Wei ; Wen, Jincai ; Wei, Ziying ; Xiao, Xiaohe ; Zhao, Jun ; Gao, Yuan ; Yang, Huijie ; Zhao, Jia ; Li, Chengwei ; Liu, Tingting ; Hou, Xiaorong ; Xu, Guang ; Chen, Yuanyuan

BACKGROUNDThe cyclic GMP-AMP synthase (cGAS)-stimulator of interferon (IFN) genes (STING) pathway is critical in the innate immune system and can be mobilized by cytosolic DNA. The various inflammatory and autoimmune diseases progression is highly correlated with aberrant cGAS-STING pathway activation. While some cGAS-STING pathway inhibitor were identified, there are no drugs that can be applied to the clinic. Compound Danshen Dripping Pill (CDDP) has been successfully used in clinic around the world, but the most common application is limited to cardiovascular disease. Therefore, the purpose of the present investigation was to examine whether CDDP inhibits the cGAS-STING pathway and could be used as a therapeutic agent for multiple cGAS-STING-triggered diseases.METHODSBMDMs, THP1 cells or Trex1^-/- BMDMs were stimulated with various cGAS-STING-agonists after pretreatment with CDDP to detect the function of CDDP on IFN-β and ISGs productionn. Next, we detect the influence on IRF3 and P65 nuclear translocation, STING oligomerization and STING-TBK1-IRF3 complex formation of CDDP. Additionally, the DMXAA-mediated activation mice model of cGAS-STING pathway was used to study the effects of CDDP. Trex1^-/- mice model and HFD-mediated obesity model were established to clarify the efficacy of CDDP on inflammatory and autoimmune diseases.RESULTSCDDP efficacy suppressed the IRF3 phosphorylation or the generation of IFN-β, ISGs, IL-6 and TNF-α. Mechanistically, CDDP did not influence the STING oligomerization and IRF3-TBK1 and STING-IRF3 interaction, but remarkably eliminated the STING-TBK1 interaction, ultimately blocking the downstream responses. In addition, we also clarified that CDDP could suppress cGAS-STING pathway activation triggered by DMXAA, in vivo. Consistently, CDDP could alleviate multi-organ inflammatory responses in Trex1^-/- mice model and attenuate the inflammatory disorders, incleding obesity-induced insulin resistance.CONCLUSIONCDDP is a specifically cGAS-STING pathway inhibitor. Furthermore, we provide novel mechanism for CDDP and discovered a clinical agent for the therapy of cGAS-STING-triggered inflammatory and autoimmune diseases.

100 Deals associated with Compound danshen dripping pills

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetic Retinopathy	CN	Tasly Pharmaceutical Group Co., Ltd.	15 Nov 2013
Angina Pectoris	RU	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	KR	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	VN	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	MN	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	SG	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	ZA	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	CN	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ablepharon Macrostomia Syndrome	Phase 3	CN	Tasly Pharmaceutical Group Co., Ltd.	20 Sep 2021
Altitude Sickness	Phase 3	US	Tasly Pharmaceuticals, Inc.	21 Jul 2021
Angina Pectoris	Phase 1	US	Arbor Pharmaceuticals LLC	06 Sep 2018
Angina, Stable	Phase 1	BY	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	CA	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	UA	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	MX	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	US	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	RU	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Phase 1	GE	Tasly Pharmaceuticals, Inc.	01 Aug 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01679028 (CTgov)	Phase 1	-	20	Placebo Group A (Placebo Group A)	xjakiluzwi(rucsmgvjkx) = exqbtjzyqj lcixuzgvuz (vjgmtppxhq, ccckdcagkv - ngtqcyzlvc) View more	-	24 Nov 2014
				T89 Group A (T89 Group A)	xjakiluzwi(rucsmgvjkx) = gbuasjjkcm lcixuzgvuz (vjgmtppxhq, edmikyzizb - swxfdszvqj) View more